PR antagonists showed promising results in second line and first line breast cancer treatment, but the development was stopped side effects such as liver toxicity, on the other hand compound that inhibited estrogen signaling such as tamoxifen in 1970s and later 20 years after aromatase inhibitors became mainstay of breast cancer therapy. This evidence concerns the gene CYP19A1 and breast cancer.